9.8
Biyoyararlanım, bir aktif ilaç bileşeninin veya terapötik kısmın sistemik dolaşıma değişmeden girme derecesini ve hızını ölçen kritik bir farmakolojik…
Biyoyararlanım, sistemik dolaşıma ulaşan değişmemiş ilaç miktarını ifade eder.
İlaçlar, biyofarmasötik sınıflandırma sistemi altında çözünürlük ve geçirgenliklerine göre dört sınıfa ayrılır.
İlaç çözünürlüğü, pH çözünürlüğü profili oluşturma ve çalkalama şişesi veya titrasyon yöntemleri ile belirlenebilir.
Bu arada, geçirgenlik belirleme yöntemleri arasında kütle dengesi farmakokinetik çalışmaları, in vivo bağırsak perfüzyon çalışmaları ve bağırsak dokusu veya epitel hücresi tek tabakaları ile geçirgenlik deneyleri yer alır.
Düşük çözünürlüğe ve geçirgenliğe sahip bazı ilaçların biyoyararlanımı zayıftır ve bu durum farmasötik, farmakokinetik ve biyolojik yaklaşımlarla aşılabilir.
Farmasötik yaklaşım, ilacın kimyasal yapısını değiştirmeden formülasyonun, üretim sürecinin veya fizikokimyasal özelliklerin değiştirilmesini içerir.
Farmakokinetik yaklaşım, ön ilaç tasarımları veya yeni kimyasal varlıklar geliştirerek ilacın kimyasal yapısını değiştirir.
Biyolojik yaklaşım, oral yollardan parenteral yollara geçiş gibi ilaç uygulama yolunun değiştirilmesini içerir.
View the full transcript and gain access to JoVE Core videos
Q1: What does bioavailability measure in pharmacology?
Bioavailability measures the amount of unchanged drug reaching the systemic circulation after administration. It reflects both the extent and rate at which an active drug ingredient enters the bloodstream, remaining chemically unchanged. This metric is critical for determining a drug's efficacy and safety profile in patients.
Q2: How does the Biopharmaceutics Classification System categorize drugs?
The Biopharmaceutics Classification System categorizes drugs into four classes based on their solubility and permeability characteristics. This classification system aids in understanding drug absorption characteristics and guiding formulation strategies. Drugs with low solubility and permeability often face challenges with poor bioavailability that require targeted enhancement approaches.
Q3: What methods are used to determine drug solubility?
Drug solubility is determined using pH-solubility profiling, which examines how solubility changes with pH, and shake-flask or titration methods, which determine solubility in different solvents or at various pH levels. These techniques help predict a drug's absorption characteristics and guide formulation development strategies for improving bioavailability.
Q4: What are the main approaches to overcome poor drug bioavailability?
Three primary approaches address poor bioavailability: the pharmaceutical approach modifies formulation, manufacturing, or physicochemical properties without changing chemical structure; the pharmacokinetic approach modifies the drug's chemical structure through prodrug designs or new chemical entities; and the biological approach changes the route of administration, such as switching from oral to parenteral routes.
Q5: How is drug permeability evaluated in bioavailability studies?
Permeability is evaluated through mass-balance pharmacokinetic studies, in vivo intestinal perfusion studies, and permeation experiments using intestinal tissue or epithelial cell monolayers. These methods help predict a drug's absorption and bioavailability by assessing how effectively the drug crosses biological membranes in the gastrointestinal tract.
Q6: What is the pharmaceutical approach to enhancing bioavailability?
The pharmaceutical approach alters the drug's formulation, manufacturing process, or physicochemical properties without changing the molecular structure. This strategy can involve using solubilizers, reducing particle size, or forming amorphous solids to improve drug dissolution and absorption, thereby enhancing bioavailability without modifying the active ingredient itself.
Q7: How does the biological approach improve drug bioavailability?
The biological approach explores alternative routes of administration to bypass limitations associated with oral bioavailability. Switching from an oral to a parenteral route allows the drug to be administered directly into the systemic circulation, avoiding the gastrointestinal tract and its absorption barriers, thereby improving overall drug bioavailability and therapeutic effectiveness.